The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure

Journal of the American College of Cardiology

Volumn 20, Issue 1, 1992, Pages 248-254

  Packer, Milton ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGITALIS; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLOSEQUINAN; HYDRALAZINE; ISOSORBIDE DINITRATE; MILRINONE; MINOXIDIL; NIFEDIPINE; PHOSPHODIESTERASE INHIBITOR; VERAPAMIL;

DISEASE COURSE; HEART FAILURE; HEMODYNAMICS; MORBIDITY; MORTALITY; NEUROENDOCRINE SYSTEM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CARDIOTONIC AGENTS; CLINICAL TRIALS; ENALAPRIL; HEART FAILURE, CONGESTIVE; HEMODYNAMICS; HUMAN; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 0026695294     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(92)90167-L     Document Type: Review

References (68)

1. Exercise ventilation and pulmonary wedge pressure in chronic stable congestive heart failure
2. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure
3. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle
4. Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure
5. Vasodilator therapy for heart failure: the influence of impedance on left ventricular performance
6. Homeometric autoregulation of the heart
7. Influence of chronic captopril therapy on the infarcted left ventricle of the rat
8. Reversible and irreversible elongation of ischemic, infarcted, and healed myocardium in response to increases in preload and afterload
9. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril
10. Effect of vasodilator therapy on, mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study
11. Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin
12. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure
13. Effects of treatment on morbidity on hypertension results in patients with diastolic blood pressures averaging 115 through 129 mm Hg
14. Effects of minoxidil on hemodynamics in patients with congestive heart failure
15. Minoxidil in patients with left heart failure: contrasting hemodynamic and clinical effects in a controlled trial
16. Calcium channel blockers in congestive heart failure: theoretic considerations and clinical experience
17. Responses of patients in heart failure to long-term oral verapamil administration (abstr)
18. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy to isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure
19. Diltiazem increases late-onset congestive heart failure in postin farction patients with early reduction in ejection fraction
20. The effect of diltiazem on mortality and reinfarction after myocardial infarction
21. Hemodynamic effects of Oral pirbuterol in chronic severe congestive heart failure
22. Evaluation of a new bipyridine inotropic agent—milrinone—in patients with severe congestive heart failure
23. Effects of milnnone on left ventricular remodeling after acute myocardial infarction
24. Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction
25. Inotropic agents increase mortality in patients with congestive heart failure (abstr)
26. Effect of oral milrinone on mortality in severe chronic heart failure
27. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure
28. Baroreceptor function in congestive heart failure: effect on neurohormonal activation and regional vascular resistance
29. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts
30. Adrenergic effects on the biology of the adult mammalian cardiocyte
31. Cardiac myocyte necrosis induced by angiotensin II
32. Nebivoloi increases survival in cardiomyopathic hamsters with congestive heart failure
33. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
34. Effect of enalapnl on survival in patients with reduced left ventricular ejection fraction and congestive heart failure
35. Effects of captopril on survival in patients with heart failure
36. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction
37. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
38. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
39. Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure
40. Comparative effects of the vasodilators flosequinan and hydralazine on the contractile function of isolated human cardiac muscle (abstr)
41. Direct myocardial and coronary effects of enalaprilat on patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique
42. Response of plasma norepinephrine to long-term administration of enalapril or hydralazine-isosorbide dinitrate in heart failure V-HeFT II (abstr)
43. Relationship of plasma norepinephrine and plasma renin activity to mortality in heart failure: V-HeFT II (abstr)
44. Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure
45. Ventricular dysfunction and necrosis produced by adrenoclhome metabolites of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy
46. Role of the sympathetic nervous system in chronic heart failure: a historical and philosophical perspective
47. Improvement in symtoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial
48. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated car- diomyopathy: a double-blind, randomized study of bucindolol versus placebo
49. Carvedilol improves left ventricular function in idiopathic dilated cardiomyopathy (abstr)
50. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure
51. Can response to β-blockcr therapy in idiopathic dilated cardiomyopathy be predicted by baseline paramelers (abstr)?
52. Which patients with chronic heart failure are most likely to show hemodynamic and functional improvement following beta-blockade (abstr)?
53. Oral milrinone increases the risk of sudden death in severe chronic heart failure: the PROMISE Trial (abstr)
54. Pathophysiologic mechanisms underlying the adverse effects of calcium channel blocking drugs in patients with chronic heart failure
55. A controlled trial of digoxin in congestive heart failure
56. Comparative effects of cantopril and digoxin in patients with mild to moderate heart failure
57. A comparison of oral milrinone, digoxin. and their combination in the treatment of patients with chronic heart failure
58. Randomized, double-blind, placebo-controlled, withdrawal study of digoxin in patients with chronic heart failure treated with converting enzyme inhibitors (abstr)
59. Sympatho-inhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings
60. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure
61. Long-term clinical, hemodynamic, angiographic, and neurohormonal responses to vasodilation wilh felodipine in patients with chronic congestive heart failure
62. Randomized multicenter double-blind placebo-controlied evalualion of amlodipine in patients with mild-to-moderate heart failure (abstr)
63. Efficacy of felodipine in congestive heart failure
64. Pharmacology of flosequinan
65. Flosequinan augments parasympathetic tone and attenuates sympathetic drive in congestive heart failure: demonstration by analysis of heart rate variability (abstr)
66. Randomized, multicenter, double-blind, placebo-controlled study of the efficacy of flosequinan, a new, long-acting vasodilator drug, in patients with chronic heart failure (abstr)
67. A randomized, multicenter, double-blind placebo controlled study of the efficacy of flosequinan in patients with chronic heart failure (abstr)
68. Neurohormonal interactions and adaptations in congestive heart failure